GNTA
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Genenta Science SpA ADR (GNTA) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Revisions (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C+ (2.7) | C (2.3) | C+ (2.8) | C (2.4) | C- (1.9) | C (2.4) |
| 2026-08-04 | C+ (2.7) | C (2.3) | C+ (2.8) | C (2.4) | C- (1.9) | C (2.4) |
| 2026-08-03 | C+ (2.7) | C (2.4) | C- (2.1) | C (2.4) | C- (2.0) | C (2.3) |
| 2026-08-02 | C+ (2.7) | C (2.4) | C- (2.1) | C (2.4) | C- (1.9) | C (2.3) |